贝伐珠单抗联合阿法替尼治疗EGFR突变的NSCLC对血清VEGF的影响及预后分析  

Effect of Bevacizumab Combined with Afatinib on Serum VEGF in NSCLC with EGFR Mutation and Prognosis Analysis

作　　者：崔洪霞[1] 郭滨[1] 蒋雪超[1] 赵宁 贾立娟[1] CUI Hongxia;GUO Bin;JIANG Xuechao;ZHAO Ning;JIA Lijuan(Department of Oncology,Binzhou Central Hospital,Binzhou,Shandong Province,251700 China)

机构地区：[1]滨州市中心医院肿瘤科,山东滨州251700

出　　处：《中外医疗》2024年第9期19-22,30,共5页China & Foreign Medical Treatment

摘　　要：目的探究在表皮生长因子受体(Epidermal Growth Factor Receptor,EGFR)突变的非小细胞肺癌(Nonsmall Cell Lung Cancer,NSCLC)患者中应用贝伐珠单抗联合阿法替尼的治疗效果以及对血清血管内皮生长因子(Vascular Endothelial Growth Factor,VEGF)及预后的影响。方法随机选取滨州市中心医院于2019年6月—2021年6月收治的70例EGFR突变的NSCLC患者为研究对象,采用随机数表法分为单一组(阿法替尼治疗)与联合组(阿法替尼联合贝伐珠单抗治疗),各35例。比较两组患者的近期效果、肿瘤标志物水平、血管生长因子水平、生存预后情况以及不良反应发生情况。结果联合组患者客观缓解率为68.57%,高于单一组的45.71%,差异有统计学意义(χ^(2)=5.777,P<0.05)。治疗后,两组患者的细胞角蛋白19片段、糖类抗原125、癌胚抗原水平、血清碱性成纤维细胞生长因子、血管内皮生长因子以及血小板衍生生长因子水平均有所降低,且联合组低于单一组,差异有统计学意义(P均<0.05)。经过30个月的随访发现,联合组患者的中位无进展生存时间、中位总生存时间长于单一组,差异有统计学意义(P均<0.05)。两组患者各项不良反应发生率对比,差异无统计学意义(P均>0.05)。结论贝伐珠单抗联合阿法替尼治疗EGFR突变的NSCLC患者的疗效显著,可明显改善患者的预后,为患者提供了更好的治疗选择和生存机会。Objective To explore the therapeutic effect of bevacizumab combined with afatinib on vascular endothelial growth factor(VEGF)and prognosis in patients with non-small cell lung cancer(NSCLC)with epidermal growth factor receptor(EGFR)mutation.Methods A total of 70 NSCLC patients with EGFR mutation admitted to Binzhou Central Hospital from June 2019 to June 2021 were randomly selected as the study objects,and were divided into single group(treated with afatinib)and combination group(treated with bevacizumab combined afatinib)according to the method of random number table,with 35 cases in each group.The short-term effect,tumor marker level,vascular growth factor level,survival prognosis and incidence of adverse reactions were compared between the two groups.Results The objec⁃tive response rate of the combination group was 68.57%,which was higher than that of the single group(45.71%),the difference was statistically significant(χ^(2)=5.777,P<0.05).After treatment,the levels of cytokeratin 19 fragment anti⁃gen 21-1,cancer antigen 125,carcinoembryonic antigen,serum basic fibroblast growth factor,vascular endothelial growth factor and platelet-derived growth factor were reduced in both groups,those of the combination group were lower than those of the single group,the differences were statistically significant(all P<0.05).After 30 months of follow-up,the median progression-free survival time and median overall survival time in the combination group were higher than those in the single group,the differences were statistically significant(both P<0.05).There was no statisti⁃cally significant difference in the incidences of adverse reactions between the two groups(all P>0.05).Conclusion The combination of bevacizumab and afatinib in the treatment of EGFR mutation NSCLC can achieve significant effec⁃tiveness include inhibition of angiogenesis,improve patient's prognosis and provide patients with better treatment op⁃tions and chances of survival.

关 键 词：贝伐珠单抗 阿法替尼 非小细胞肺癌 EGFR突变 

分 类 号：R73[医药卫生—肿瘤]